Search

Your search keyword '"Finke, Christy"' showing total 918 results
Start Over Author "Finke, Christy"
918 results on '"Finke, Christy"'

151. Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations

Author

Pophali, Prateek, primary, Lasho, Terra L., additional, Finke, Christy, additional, Horna, Pedro, additional, Ketterling, Rhett P., additional, Gangat, Naseema, additional, Begna, Kebede H., additional, Mangaonkar, Abhishek A., additional, Pardanani, Animesh, additional, Tefferi, Ayalew, additional, and Patnaik, Mrinal M., additional

Published
2018
Full Text
View/download PDF

152. 3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Author

Szuber, Natasha, primary, Mudireddy, Mythri, additional, Nicolosi, Maura, additional, Penna, Domenico, additional, Vallapureddy, Rangit, additional, Lasho, Terra L., additional, Finke, Christy, additional, Begna, Kebede H., additional, Elliott, Michelle A., additional, Hook, C. Christopher, additional, Wolanskyj, Alexandra, additional, Patnaik, Mrinal M., additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, Sirhan, Shireen, additional, Pardanani, Animesh, additional, Gangat, Naseema, additional, Busque, Lambert, additional, and Tefferi, Ayalew, additional

Published
2018
Full Text
View/download PDF

153. Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients

Author

Pophali, Prateek, primary, Horna, Pedro, additional, Lasho, Terra L., additional, Finke, Christy M., additional, Ketterling, Rhett P., additional, Gangat, Naseema, additional, Nagorney, David, additional, Tefferi, Ayalew, additional, and Patnaik, Mrinal M., additional

Published
2018
Full Text
View/download PDF

159. JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2 V617F mutated disease

Author

Tefferi, Ayalew, primary, Lavu, Sravanthi, additional, Mudireddy, Mythri, additional, Lasho, Terra L., additional, Finke, Christy M., additional, Gangat, Naseema, additional, Pardanani, Animesh, additional, Hanson, Curtis A., additional, Mannarelli, Carmela, additional, Guglielmelli, Paola, additional, and Vannucchi, Alessandro M., additional

Published
2018
Full Text
View/download PDF

160. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model

Author

Gangat, Naseema, primary, Mudireddy, Mythri, additional, Lasho, Terra L., additional, Finke, Christy M., additional, Nicolosi, Maura, additional, Szuber, Natasha, additional, Patnaik, Mrinal M., additional, Pardanani, Animesh, additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, and Tefferi, Ayalew, additional

Published
2018
Full Text
View/download PDF

162. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients

Author

Tefferi, Ayalew, primary, Nicolosi, Maura, additional, Mudireddy, Mythri, additional, Szuber, Natasha, additional, Finke, Christy M., additional, Lasho, Terra L., additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, Pardanani, Animesh, additional, Gangat, Naseema, additional, Mannarelli, Carmela, additional, Fanelli, Tiziana, additional, Guglielmelli, Paola, additional, and Vannucchi, Alessandro M., additional

Published
2017
Full Text
View/download PDF

165. Monocytosis in polycythemia vera: Clinical and molecular correlates

Author

Barraco, Daniela, primary, Cerquozzi, Sonia, additional, Gangat, Naseema, additional, Patnaik, Mrinal M., additional, Lasho, Terra, additional, Finke, Christy, additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, Pardanani, Animesh, additional, and Tefferi, Ayalew, additional

Published
2017
Full Text
View/download PDF

167. Spectrum of abnormalities and clonal transformation in germline RUNX1familial platelet disorder and a genomic comparative analysis with somatic RUNX1mutations in MDS/MPN overlap neoplasms

Author

DiFilippo, Emma C., Coltro, Giacomo, Carr, Ryan M., Mangaonkar, Abhishek A., Binder, Moritz, Khan, Shakila P., Rodriguez, Vilmarie, Gangat, Naseema, Wolanskyj, Alexandra, Pruthi, Rajiv K., Chen, Dong, He, Rong, Viswanatha, David S., Lasho, Terra, Finke, Christy, Tefferi, Ayalew, Pardanani, Animesh, and Patnaik, Mrinal M.

Published
2020
Full Text
View/download PDF

168. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients

Author

Coltro, Giacomo, Mangaonkar, Abhishek A., Lasho, Terra L., Finke, Christy M., Pophali, Prateek, Carr, Ryan, Gangat, Naseema, Binder, Moritz, Pardanani, Animesh, Fernandez-Zapico, Martin, Robertson, Keith D., Bosi, Alberto, Droin, Nathalie, Vannucchi, Alessandro M., Tefferi, Ayalew, Hunter, Anthony, Padron, Eric, Solary, Eric, and Patnaik, Mrinal M.

Abstract

Loss-of-function TET2mutations (TET2MT) are frequent early clonal events in myeloid neoplasms and are thought to confer a fitness advantage to hematopoietic precursors. This large, multi-institutional study (n= 1084), investigated the TET2mutational landscape and prognostic implications of the number, type, and location of TET2MTand the epistatic relationship with other somatic events in chronic myelomonocytic leukemia (CMML). Nine hundred and forty-two TET2MTwere identified in 604 (56%) patients, of which 710 (75%) were predicted to be truncating (involving the catalytic domain). Three hundred and sixteen (29%) patients had ≥1 TET2MT, with 28%, 1%, and 0.2% harboring 2, 3, and 5 mutations, respectively. In comparison to TET2WT, TET2MTpatients were older in age, more likely to have dysplastic CMML, a higher number of co-occurring mutations, and lower-risk stratification. Importantly, TET2MTwere associated with a survival advantage (49 vs. 30 months, p< 0.0001), especially in the context of multiple TET2MT(≥2; 57 months, p< 0.001), and truncating TET2MT(51 months, p< 0.001). In addition, the adverse prognostic impact of ASXL1MTwas partially mitigated by concurrent TET2MT, with the ASXL1WT/TET2MTgenotype having better outcomes and resulting in further risk stratification of ASXL1inclusive CMML prognostic models, in comparison to ASXL1MTalone.

Published
2020
Full Text
View/download PDF

171. Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study.

Author

Kusne, Yael, Lasho, Terra, Finke, Christy, Elsabbagh, Zaid, McCue, Shaylene, Hobday, Timothy, Starr, Jason, Bekaii-Saab, Tanios, Halfdanarson, Thorvardur R., Patnaik, Mrinal M., Ou, Fang-Shu, and Sonbol, Mohamad Bassam

Subjects
*NEUROENDOCRINE tumors, *THROMBOCYTOPENIA, *HEMATOPOIESIS, *ALKYLATING agents, *PEPTIDE receptors
Abstract

PURPOSE: Thrombocytopenia is a relatively common dose-limiting toxicity during peptide receptor radionuclide therapy (PRRT) in patients with NET. Although uncommon, some patients develop persistent cytopenia and eventually therapy-related myeloid neoplasm (t-MN), which has a dismal prognosis. As the indications for PRRT are expanding, it is important to investigate factors that may predict cytopenias during/after PRRT. We prospectively evaluated the prevalence of clonal hematopoiesis (CH) and cytopenia in patients with NET undergoing PRRT. MATERIALS AND METHODS: Patients with metastatic NET with plan to receive four cycles of lutetium-177 were enrolled. CH was evaluated before PRRT using a panel of 220 genes with a targeted depth of ≥1,000×. Patients were followed during PRRT and every 3 months thereafter. RESULTS: Of 37 patients enrolled, the median age was 68 years and 51.4% were male. Previous treatment exposures included alkylating agents in 30%, platinum agents in 8%, and external radiation in 13%. CH was detected in 35.1% using a variant allele frequency (VAF) cutoff of ≥2% and 45.9% with a VAF of ≥1%. The most common mutations were in age-related genes (DNMT3A , TET2). CH was not associated with anemia or neutropenia; however, it was associated with lower platelet count at baseline and more time spent in a thrombocytopenic state during/after PRRT. Five patients had bone marrow biopsies (BMBs) because of sustained hematologic dysfunction post-PRRT, and of those, diagnoses included clonal cytopenia of undetermined significance (CCUS) in three and idiopathic cytopenia of undetermined significance (ICUS) in two. CONCLUSION: CH is present in 35.1% of patients with NET and is associated with thrombocytopenia risk during PRRT. Future studies with long-term follow-up will delineate whether CH might be a predictor for higher risk of t-MN after PRRT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

172. Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors.

Author

Vaa, Brianna, Tefferi, Ayalew, Gangat, Naseema, Pardanani, Animesh, Lasho, Terra, Finke, Christy, Wolanskyj, Alexandra, Vaa, Brianna E, Lasho, Terra L, Finke, Christy M, and Wolanskyj, Alexandra P

Subjects
ITCHING, MYELOFIBROSIS, PARTIAL response continuous phase modulation, THROMBOCYTOPENIA, MYELOPROLIFERATIVE neoplasms, POLYCYTHEMIA vera
Abstract

Primary myelofibrosis (PMF)-associated pruritus is often severe and requires treatment. Fifty-one patients with bone marrow-proven PMF with associated pruritus were identified from a primary cohort of patients with PMF (n = 566) seen at our institution. We conducted a retrospective review of the clinical characteristics, severity of pruritus, type of treatment, and response of these patients. Thirty-two out of 51 patients (63 %) reported severe PMF-associated pruritus and required a total of 108 treatment episodes, with complete response (CR), partial response (PR) and no response (NR) observed in 22, 23, and 55 % of episodes, respectively. The most common treatment categories included JAK inhibitors (n = 19), anti-depressants (n = 18), and antihistamines (n = 17). Highest CR rates were observed in patients treated with a JAK inhibitor (53 %) and immunomodulatory drugs (IMiDS (50 %)). Emerging targeted therapies may result in better symptom control and higher response rates in patients suffering from severe PMF-associated pruritus. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

175. Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia

Author

Patnaik, Mrinal M, primary, Barraco, Daniela, additional, Lasho, Terra L., additional, Tolosa, Ezequiel, additional, Almada, Luciana L., additional, Davila, Jaime I, additional, Finke, Christy, additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, Solary, Éric, additional, Droin, Nathalie M., additional, Gangat, Naseema, additional, Al-Kali, Aref, additional, Fernandez-Zapico, Martin E., additional, and Tefferi, Ayalew, additional

Published
2016
Full Text
View/download PDF

181. Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates

Author

Patnaik, Mrinal M, primary, Zahid, Mohammad Faizan, additional, Lasho, Terra L., additional, Tolosa, Ezequiel, additional, Finke, Christy, additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, Solary, Eric, additional, Robertson, Keith D, additional, Gangat, Naseema, additional, Fernandez-Zapico, Martin E., additional, and Tefferi, Ayalew, additional

Published
2016
Full Text
View/download PDF

182. Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates

Author

Barraco, Daniela, primary, Cerquozzi, Sonia, additional, Gangat, Naseema, additional, Patnaik, Mrinal M, additional, Lasho, Terra L., additional, Finke, Christy, additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, Pardanani, Animesh, additional, and Tefferi, Ayalew, additional

Published
2016
Full Text
View/download PDF

183. Targeted deep sequencing in primary myelofibrosis

Author

Tefferi, Ayalew, primary, Lasho, Terra L., additional, Finke, Christy M., additional, Elala, Yoseph, additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, Gangat, Naseema, additional, and Pardanani, Animesh, additional

Published
2016
Full Text
View/download PDF

184. Targeted deep sequencing in polycythemia vera and essential thrombocythemia

Author

Tefferi, Ayalew, primary, Lasho, Terra L., additional, Guglielmelli, Paola, additional, Finke, Christy M., additional, Rotunno, Giada, additional, Elala, Yoseph, additional, Pacilli, Annalisa, additional, Hanson, Curtis A., additional, Pancrazzi, Alessandro, additional, Ketterling, Rhett P., additional, Mannarelli, Carmela, additional, Barraco, Daniela, additional, Fanelli, Tiziana, additional, Pardanani, Animesh, additional, Gangat, Naseema, additional, and Vannucchi, Alessandro M., additional

Published
2016
Full Text
View/download PDF

193. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients

Author

Mangaonkar, Abhishek A., Swoboda, David M., Coltro, Giacomo, Lasho, Terra L., Novotny, Paul J., Pophali, Prateek, Carr, Ryan M., Binder, Moritz, Finke, Christy M., Gangat, Naseema, Al-Kali, Aref, Begna, Kebede H., Reichard, Kaaren K., Ketterling, Rhett P., Al Ali, Najla H., Vafaii, Pardis, Zhang, Ling, Padron, Eric, Talati, Chetasi, and Patnaik, Mrinal M.

Published
2020
Full Text
View/download PDF

194. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Author

Szuber, Natasha, Mudireddy, Mythri, Nicolosi, Maura, Penna, Domenico, Vallapureddy, Rangit R., Lasho, Terra L., Finke, Christy, Begna, Kebede H., Elliott, Michelle A., Hook, C. Christopher, Wolanskyj, Alexandra P., Patnaik, Mrinal M., Hanson, Curtis A., Ketterling, Rhett P., Sirhan, Shireen, Pardanani, Animesh, Gangat, Naseema, Busque, Lambert, and Tefferi, Ayalew

Abstract

To document the Mayo Clinic decades-long experience with myeloproliferative neoplasms (MPNs) and provide mature risk-stratified survival data and disease complication estimates.

Published
2019
Full Text
View/download PDF

197. Pilot Prospective Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Vexas Syndrome

Author

Mangaonkar, Abhishek, Langer, Kimberly J., Lasho, Terra, Finke, Christy, Litzow, Mark R., Hogan, William J., Shah, Mithun V., Go, Ronald S., Bartoo, Gabriel, Kutzke, Jade L, McCullough, Kristen, Koster, Matthew J, Warrington, Kenneth J., Reichard, Kaaren K., Olteanu, Horatiu, Riwes, Mary Mansour, Patnaik, Mrinal M., and Alkhateeb, Hassan B.

Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an autoinflammatory condition due to UBA1mutations with limited therapeutic options. Previously, we reported preliminary outcomes on a series of 5 patients with VEXAS treated with allogeneic hematopoietic stem cell transplantation (alloHCT, Mangaonkar A et al. Am J Hematol2023). In this abstract, we present long-term, prospective follow-up data on an expanded cohort of 10 VEXAS patients [including 1 with a haploidentical donor (haploHCT)] treated with alloHCT.

Published
2024
Full Text
View/download PDF

198. High-dose IV ascorbic acid therapy for patients with CCUS with TET2mutations

Author

Xie, Zhuoer, Fernandez, Jenna, Lasho, Terra, Finke, Christy, Amundson, Michelle, McCullough, Kristen B., LaPlant, Betsy R., Mangaonkar, Abhishek A., Gangat, Naseema, Reichard, Kaaren K., Elliott, Michelle, Witzig, Thomas E., and Patnaik, Mrinal M.

Abstract

This phase 2 trial assessed high-dose IV ascorbic acid in TET2mutant clonal cytopenia. Eight of 10 patients were eligible for response assessment, with no responses at week 20 by International Working Group Myelodysplasia Syndromes/Neoplasms criteria. This trial was registered at www.clinicaltrials.govas #NCT03418038.

Published
2024
Full Text
View/download PDF

200. Molecular Correlates of Anemia in Primary Myelofibrosis

Author

Barraco, Daniela, primary, Lasho, Terra L., additional, Begna, Kebede H., additional, Gangat, Naseema, additional, Finke, Christy, additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, Pardanani, Animesh, additional, and Tefferi, Ayalew, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results